Adverum Biotechnologies Inc - Company Profile
Powered by 
All the sales intelligence you need on Adverum Biotechnologies Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Adverum Biotechnologies Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Adverum Biotechnologies Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Adverum Biotechnologies Inc (Adverum), a subsidiary of Eli Lilly and Co, is a clinical-stage company that develops gene therapy products to treat ocular diseases. Its pipeline products include Ixo-vec which treats wet age-related macular degeneration; AAV.7m8.CFI Gtx, LSV1.CFI Gtx and AAV.7m8.CaMeRaOpsin Gtx for geographic atrophy; AAV.7m8 Gtx for GS030 and AAV.7m8 Gtx for RTx-015 which targets retinitis pigmentosa; LX2006 GTX which treats friedreich's ataxia; ADVM-062 for blue cone monochromacy; and ADVM-082 which targets achromatopsia. The company utilizes its proprietary intravitreal platform and an engineered AAV.7m8 vector to deliver a genetic blueprint directly into retinal cells via a single injection. Adverum is headquartered in Redwood City, California, the US.
Headquarters
United States of America
Address
100 Cardinal Way, Redwood City, California, 94063
Website
adverum.com
Telephone
1 650 6569323
No of Employees
155
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$1.0M
Adverum Biotechnologies Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Ixo-vec: Wet Age-Related Macular Degeneration |
| Geographic Atrophy: |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company entered into an agreement to be acquired by Eli Lilly and Co. |
| 2024 | Regulatory Approval | In August, the company received approval for Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration for Ixo-vec, its clinical-stage gene therapy product candidate, for treating wet AMD. |
| 2023 | Regulatory Approval | In April, the company announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency granted Ixo-vec , an investigational gene therapy for the treatment of wet AMD. |
Competitor Comparison
| Key Parameters | Adverum Biotechnologies Inc | Kriya Therapeutics Inc | Ray Therapeutics Inc | ONL Therapeutics Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Redwood City | Palo Alto | Berkeley | Ann Arbor |
| State/Province | California | California | California | Michigan |
| No. of Employees | 155 | - | - | - |
| Entity Type | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| R. Andrew Ramelmeier, Ph.D. | Chief Technology Officer | Senior Management | - | - |
| Dena House | Chief People Officer | Senior Management | - | - |
| Rabia Gurses Ozden, MD | Chief Medical Officer | Senior Management | - | - |
| Romuald Corbau, Ph.D. | Chief Scientific Officer | Senior Management | - | - |
| Carla Fiankan | Senior Vice President - Regulatory Affairs | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer